Pregnancy and thrombophilia

References

• Bremme KA. Haemostatic changes in pregnancy. Best Pract. Res. Clin. Haematol.16(2), 153–168 (2003).
   PubMed Web of Science ®Google Scholar
• Ginsberg JS, Brill-Edwards P, Burrows RF et al. Venous thrombosis during pregnancy: leg and trimester of presentation. Thromb. Haemost.67(5), 519–520 (1992).
   PubMed Web of Science ®Google Scholar
• Beller FK, Ebert C. The coagulation and fibrinolytic enzyme system in pregnancy and in the puerperium. Eur. J. Obstet. Gynecol. Reprod. Biol.13(3), 177–197 (1982).
   PubMed Web of Science ®Google Scholar
• Stirling Y, Woolf L, North WR, Seghatchian MJ, Meade TW. Haemostasis in normal pregnancy. Thromb. Haemost.52(2), 176–182 (1984).
   PubMed Web of Science ®Google Scholar
• Cerneca F, Ricci G, Simeone R, Malisano M, Alberico S, Guaschino S. Coagulation and fibrinolysis changes in normal pregnancy. Increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with a reactive fibrinolysis. Eur. J. Obstet. Gynecol. Reprod. Biol.73(1), 31–36 (1997).
   PubMed Web of Science ®Google Scholar
• Condie RG. A serial study of coagulation factors XII, XI and X in plasma in normal pregnancy and in pregnancy complicated by pre-eclampsia. Br. J. Obstet. Gynaecol.83(8), 636–639 (1976).
   PubMedGoogle Scholar
• Kjellberg U, Andersson NE, Rosen S, Tengborn L, Hellgren M. APC resistance and other haemostatic variables during pregnancy and puerperium. Thromb. Haemost.81(4), 527–531 (1999).
   PubMed Web of Science ®Google Scholar
• Lefkowitz JB, Clarke SH, Barbour LA. Comparison of protein S functional and antigenic assays in normal pregnancy. Am. J. Obstet. Gynecol.175(3 Pt 1), 657–660 (1996).
   PubMed Web of Science ®Google Scholar
• Comp PC, Thurnau GR, Welsh J, Esmon CT. Functional and immunologic protein S levels are decreased during pregnancy. Blood68(4), 881–885 (1986).
   PubMed Web of Science ®Google Scholar
• Faught W, Garner P, Jones G, Ivey B. Changes in protein C and protein S levels in normal pregnancy. Am. J. Obstet. Gynecol.172(1 Pt 1), 147–150 (1995).
   PubMed Web of Science ®Google Scholar
• Cumming AM, Tait RC, Fildes S, Yoong A, Keeney S, Hay CR. Development of resistance to activated protein C during pregnancy. Br. J. Haematol.90(3), 725–727 (1995).
   PubMed Web of Science ®Google Scholar
• Mathonnet F, de Mazancourt P, Bastenaire B et al. Activated protein C sensitivity ratio in pregnant women at delivery. Br. J. Haematol.92(1), 244–246 (1996).
   PubMed Web of Science ®Google Scholar
• Ishii A, Yamada S, Yamada R, Hamada H. t-PA activity in peripheral blood obtained from pregnant women. J. Perinat. Med.22(2), 113–117 (1994).
   PubMed Web of Science ®Google Scholar
• Nilsson IM, Felding P, Lecander I, Lenner C, Astedt B. Different types of plasminogen activator inhibitors in plasma and platelets in pregnant women. Br. J. Haematol.62(2), 215–220 (1986).
   PubMed Web of Science ®Google Scholar
• Lecander I, Astedt B. Specific plasminogen activator inhibitor of placental type PAI 2 occurring in amniotic fluid and cord blood. J. Lab. Clin. Med.110(5), 602–605 (1987).
   PubMed Web of Science ®Google Scholar
• Astedt B, Hagerstrand I, Lecander I. Cellular localisation in placenta of placental type plasminogen activator inhibitor. Thromb. Haemost.56(1), 63–65 (1986).
   PubMed Web of Science ®Google Scholar
• de Boer K, ten Cate JW, Sturk A, Borm JJ, Treffers PE. Enhanced thrombin generation in normal and hypertensive pregnancy. Am. J. Obstet. Gynecol.160(1), 95–100 (1989).
   PubMed Web of Science ®Google Scholar
• Chabloz P, Reber G, Boehlen F, Hohlfeld P, de Moerloose P. TAFI antigen and d-dimer levels during normal pregnancy and at delivery. Br. J. Haematol.115(1), 150–152 (2001).
   PubMed Web of Science ®Google Scholar
• Ghirardini G, Battioni M, Bertellini C, Colombini R, Colla R, Rossi G. d-dimer after delivery in uncomplicated pregnancies. Clin. Exp. Obstet. Gynecol.26(3–4), 211–212 (1999).
   PubMedGoogle Scholar
• Sheppard BL, Bonnar J. Uteroplacental hemostasis in intrauterine fetal growth retardation. Semin. Thromb. Hemost.25(5), 443–446 (1999).
   PubMed Web of Science ®Google Scholar
• Knight M, Redman CW, Linton EA, Sargent IL. Shedding of syncytiotrophoblast microvilli into the maternal circulation in pre-eclamptic pregnancies. Br. J. Obstet. Gynaecol.105(6), 632–640 (1998).
   PubMedGoogle Scholar
• Lindqvist P, Dahlback B, Marsal K. Thrombotic risk during pregnancy: a population study. Obstet. Gynecol.94(4), 595–599 (1999).
   PubMed Web of Science ®Google Scholar
• Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet353(9160), 1258–1265 (1999).
   PubMed Web of Science ®Google Scholar
• Eldor A. Thrombophilia, thrombosis and pregnancy. Thromb. Haemost.86(1), 104–111 (2001).
   PubMed Web of Science ®Google Scholar
• James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am. J. Obstet. Gynecol.194(5), 1311–1315 (2006).
   PubMed Web of Science ®Google Scholar
• Macklon NS, Greer IA, Bowman AW. An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy. Br. J. Obstet. Gynaecol.104(2), 191–197 (1997).
   PubMedGoogle Scholar
• Martinelli I, De Stefano V, Taioli E, Paciaroni K, Rossi E, Mannucci PM. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb. Haemost.87(5), 791–795 (2002).
   PubMed Web of Science ®Google Scholar
• Ray JG, Chan WS. Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and the leg of presentation. Obstet. Gynecol. Surv.54(4), 265–271 (1999).
   PubMedGoogle Scholar
• Macklon NS, Greer IA. Venous thromboembolic disease in obstetrics and gynaecology: the Scottish experience. Scott. Med. J.41(3), 83–86 (1996).
   PubMed Web of Science ®Google Scholar
• Pabinger I, Grafenhofer H, Kyrle PA et al. Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. Blood100(3), 1060–1062 (2002).
   PubMed Web of Science ®Google Scholar
• Conard J, Horellou MH, Van Dreden P, Lecompte T, Samama M. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb. Haemost.63(2), 319–320 (1990).
   PubMed Web of Science ®Google Scholar
• De Stefano V, Leone G, Mastrangelo S et al. Clinical manifestations and management of inherited thrombophilia: retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb. Haemost.72(3), 352–358 (1994).
   PubMed Web of Science ®Google Scholar
• De Stefano V, Leone G, Mastrangelo S et al. Thrombosis during pregnancy and surgery in patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb. Haemost.71(6), 799–800 (1994).
   PubMed Web of Science ®Google Scholar
• Dahlback B. Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood85(3), 607–614 (1995).
   PubMed Web of Science ®Google Scholar
• Dahlback B. Thrombophilia: the discovery of activated protein C resistance. Adv. Genet.33, 135–175 (1995).
   PubMed Web of Science ®Google Scholar
• Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood85(6), 1504–1508 (1995).
   PubMed Web of Science ®Google Scholar
• Bokarewa MI, Bremme K, Blomback M. Arg506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br. J. Haematol.92(2), 473–478 (1996).
   PubMed Web of Science ®Google Scholar
• Hallak M, Senderowicz J, Cassel A et al. Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy. Am. J. Obstet. Gynecol.176(4), 889–893 (1997).
   PubMed Web of Science ®Google Scholar
• Gerhardt A, Scharf RE, Beckmann MW et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N. Engl. J. Med.342(6), 374–380 (2000).
   PubMed Web of Science ®Google Scholar
• Dizon-Townson D, Miller C, Sibai B et al. The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus. Obstet. Gynecol.106(3), 517–524 (2005).
   PubMed Web of Science ®Google Scholar
• Gerhardt A, Scharf RE, Zotz RB. Effect of hemostatic risk factors on the individual probability of thrombosis during pregnancy and the puerperium. Thromb. Haemost.90(1), 77–85 (2003).
   PubMed Web of Science ®Google Scholar
• McColl MD, Ellison J, Reid F, Tait RC, Walker ID, Greer IA. Prothrombin 20210 G-->A, MTHFR C677T mutations in women with venous thromboembolism associated with pregnancy. Br. J. Obstet. Gynaecol.107(4), 565–569 (2000).
   Google Scholar
• Greer IA. The challenge of thrombophilia in maternal–fetal medicine. N. Engl. J. Med.342(6), 424–425 (2000).
   PubMed Web of Science ®Google Scholar
• Petri M. Epidemiology of the antiphospholipid antibody syndrome. J. Autoimmun.15(2), 145–151 (2000).
   PubMed Web of Science ®Google Scholar
• Pattison NS, Chamley LW, McKay EJ, Liggins GC, Butler WS. Antiphospholipid antibodies in pregnancy: prevalence and clinical associations. Br. J. Obstet. Gynaecol.100(10), 909–913 (1993).
   PubMedGoogle Scholar
• MacLean MA, Cumming GP, McCall F, Walker ID, Walker JJ. The prevalence of lupus anticoagulant and anticardiolipin antibodies in women with a history of first trimester miscarriages. Br. J. Obstet. Gynaecol.101(2), 103–106 (1994).
   PubMedGoogle Scholar
• Asherson RA, Khamashta MA, Ordi-Ros J et al. The “primary” antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore)68(6), 366–374 (1989).
   PubMed Web of Science ®Google Scholar
• Ginsburg KS, Liang MH, Newcomer L et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann. Intern. Med.117(12), 997–1002 (1992).
   PubMed Web of Science ®Google Scholar
• Ahmed E, Stegmayr B, Trifunovic J, Weinehall L, Hallmans G, Lefvert AK. Anticardiolipin antibodies are not an independent risk factor for stroke: an incident case-referent study nested within the MONICA and Vasterbotten cohort project. Stroke31(6), 1289–1293 (2000).
   PubMed Web of Science ®Google Scholar
• Vila P, Hernandez MC, Lopez-Fernandez MF, Batlle J. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb. Haemost.72(2), 209–213 (1994).
   PubMed Web of Science ®Google Scholar
• Hammerslough CR. Estimating the probability of spontaneous abortion in the presence of induced abortion and vice versa.Public Health Rep.107(3), 269–277 (1992).
   PubMed Web of Science ®Google Scholar
• Rai R, Regan L, Hadley E, Dave M, Cohen H. Second-trimester pregnancy loss is associated with activated C resistance. Br. J. Haematol.92(2), 489–490 (1996).
   PubMed Web of Science ®Google Scholar
• Pauer HU, Neesen J, Hinney B. Factor V Leiden and its relevance in patients with recurrent abortions. Am. J. Obstet. Gynecol.178(3), 629 (1998).
   PubMed Web of Science ®Google Scholar
• Kovalevsky G, Gracia CR, Berlin JA, Sammel MD, Barnhart KT. Evaluation of the association between hereditary thrombophilias and recurrent pregnancy loss: a meta-analysis. Arch. Intern. Med.164(5), 558–563 (2004).
   PubMed Web of Science ®Google Scholar
• Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet361(9361), 901–908 (2003).
   PubMed Web of Science ®Google Scholar
• Lockshin MD, Druzin ML, Goei S et al. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. N. Engl. J. Med.313(3), 152–156 (1985).
   PubMed Web of Science ®Google Scholar
• Lockshin MD. Lupus pregnancy. Clin. Rheum. Dis.11(3), 611–632 (1985).
   PubMedGoogle Scholar
• Branch DW, Silver R, Pierangeli S, van Leeuwen I, Harris EN. Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome. Obstet. Gynecol.89(4), 549–555 (1997).
   PubMed Web of Science ®Google Scholar
• Bocciolone L, Meroni P, Parazzini F et al. Antiphospholipid antibodies and risk of intrauterine late fetal death. Acta Obstet. Gynecol. Scand.73(5), 389–392 (1994).
   PubMed Web of Science ®Google Scholar
• Meroni PL, di Simone N, Testoni C, D’Asta M, Acaia B, Caruso A. Antiphospholipid antibodies as cause of pregnancy loss. Lupus13(9), 649–652 (2004).
   PubMed Web of Science ®Google Scholar
• Rand JH, Wu XX, Guller S et al. Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am. J. Obstet. Gynecol.171(6), 1566–1572 (1994).
   PubMed Web of Science ®Google Scholar
• Chamley LW, Pattison NS, Liddell H. β2 glycoprotein I-dependent anticardiolipin antibodies in recurrent miscarriage. Hum. Reprod.13(7), 2033–2034 (1998).
   PubMed Web of Science ®Google Scholar
• Chamley LW, Duncalf AM, Mitchell MD, Johnson PM. Action of anticardiolipin and antibodies to β2-glycoprotein-I on trophoblast proliferation as a mechanism for fetal death. Lancet352(9133), 1037–1038 (1998).
   PubMed Web of Science ®Google Scholar
• Sthoeger ZM, Mozes E, Tartakovsky B. Anti-cardiolipin antibodies induce pregnancy failure by impairing embryonic implantation. Proc. Natl Acad. Sci. USA90(14), 6464–6467 (1993).
   PubMed Web of Science ®Google Scholar
• Lyden TW, Vogt E, Ng AK, Johnson PM, Rote NS. Monoclonal antiphospholipid antibody reactivity against human placental trophoblast. J. Reprod. Immunol.22(1), 1–14 (1992).
   PubMed Web of Science ®Google Scholar
• Bonet B, Hauge-Gillenwater H, Zhu XD, Knopp RH. LDL oxidation and human placental trophoblast and macrophage cytotoxicity. Proc. Soc. Exp. Biol. Med.217(2), 203–211 (1998).
   PubMed Web of Science ®Google Scholar
• Horkko S, Miller E, Dudl E et al. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J. Clin. Invest.98(3), 815–825 (1996).
   PubMed Web of Science ®Google Scholar
• Holers VM, Girardi G, Mo L et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J. Exp. Med.195(2), 211–220 (2002).
   PubMed Web of Science ®Google Scholar
• Saftlas AF, Olson DR, Franks AL, Atrash HK, Pokras R. Epidemiology of preeclampsia and eclampsia in the United States, 1979–1986. Am. J. Obstet. Gynecol.163(2), 460–465 (1990).
   PubMed Web of Science ®Google Scholar
• Dekker GA, de Vries JI, Doelitzsch PM et al. Underlying disorders associated with severe early-onset preeclampsia. Am. J. Obstet. Gynecol.173(4), 1042–1048 (1995).
   PubMed Web of Science ®Google Scholar
• Kupferminc MJ, Eldor A, Steinman N et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N. Engl. J. Med.340(1), 9–13 (1999).
   PubMed Web of Science ®Google Scholar
• Livingston JC, Barton JR, Park V, Haddad B, Phillips O, Sibai BM. Maternal and fetal inherited thrombophilias are not related to the development of severe preeclampsia. Am. J. Obstet. Gynecol.185(1), 153–157 (2001).
   PubMed Web of Science ®Google Scholar
• De Maat MP, Jansen MW, Hille ET et al. Preeclampsia and its interaction with common variants in thrombophilia genes. J. Thromb. Haemost.2(9), 1588–1593 (2004).
   PubMed Web of Science ®Google Scholar
• D’Anna R, Baviera G, Corrado F, Ientile R, Granese D, Stella NC. Plasma homocysteine in early and late pregnancies complicated with preeclampsia and isolated intrauterine growth restriction. Acta Obstet. Gynecol. Scand.83(2), 155–158 (2004).
   PubMed Web of Science ®Google Scholar
• von Tempelhoff GF, Heilmann L, Spanuth E, Kunzmann E, Hommel G. Incidence of the factor V Leiden-mutation, coagulation inhibitor deficiency, and elevated antiphospholipid-antibodies in patients with preeclampsia or HELLP-syndrome. Hemolysis, elevated liver-enzymes, low platelets. Thromb. Res.100(4), 363–365 (2000).
   PubMed Web of Science ®Google Scholar
• de Vries JI, Dekker GA, Huijgens PC, Jakobs C, Blomberg BM, van Geijn HP. Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies. Br. J. Obstet. Gynaecol.104(11), 1248–1254 (1997).
   PubMedGoogle Scholar
• Kupferminc MJ, Many A, Bar-Am A, Lessing JB, Ascher-Landsberg J. Mid-trimester severe intrauterine growth restriction is associated with a high prevalence of thrombophilia. Br. J. Obstet. Gynaecol.109(12), 1373–1376 (2002).
   Google Scholar
• Infante-Rivard C, Rivard GE, Yotov WV et al. Absence of association of thrombophilia polymorphisms with intrauterine growth restriction. N. Engl. J. Med.347(1), 19–25 (2002).
   PubMed Web of Science ®Google Scholar
• van der Molen EF, Verbruggen B, Novakova I, Eskes TK, Monnens LA, Blom HJ. Hyperhomocysteinemia and other thrombotic risk factors in women with placental vasculopathy. Br. J. Obstet. Gynaecol.107(6), 785–791 (2000).
   Google Scholar
• Lagrange F, Vergnes C, Brun JL et al. Absence of placental transfer of pentasaccharide (fondaparinux, arixtra) in the dually perfused human cotyledon in vitro.Thromb. Haemost.87(5), 831–835 (2002).
   PubMed Web of Science ®Google Scholar
• Harenberg J. Treatment of a woman with lupus and thromboembolism and cutaneous intolerance to heparins using fondaparinux during pregnancy. Thromb. Res.119(3), 385–388 (2007).
   PubMed Web of Science ®Google Scholar
• Flessa HC, Kapstrom AB, Glueck HI, Will JJ. Placental transport of heparin. Am. J. Obstet. Gynecol.93(4), 570–573 (1965).
   PubMed Web of Science ®Google Scholar
• Forestier F, Daffos F, Rainaut M, Toulemonde F. Low molecular weight heparin (CY 216) does not cross the placenta during the third trimester of pregnancy. Thromb. Haemost.57(2), 234 (1987).
   PubMed Web of Science ®Google Scholar
• Ginsberg JS, Hirsh J. Anticoagulants during pregnancy. Annu. Rev. Med.40, 79–86 (1989).
   PubMed Web of Science ®Google Scholar
• Ginsberg JS, Hirsh J, Turner DC, Levine MN, Burrows R. Risks to the fetus of anticoagulant therapy during pregnancy. Thromb. Haemost.61(2), 197–203 (1989).
   PubMed Web of Science ®Google Scholar
• Hall JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am. J. Med.68(1), 122–140 (1980).
   PubMed Web of Science ®Google Scholar
• Pauli RM, Hall JG, Wilson KM. Risks of anticoagulation during pregnancy. Am. Heart J.100(5), 761–762 (1980).
   PubMed Web of Science ®Google Scholar
• Weitz JI. Low-molecular-weight heparins. N. Engl. J. Med.337(10), 688–698 (1997).
   PubMed Web of Science ®Google Scholar
• Blomback M, Bremme K, Hellgren M, Lindberg H. A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. Blood Coagul. Fibrinolysis9(4), 343–350 (1998).
   PubMed Web of Science ®Google Scholar
• Rodie VA, Thomson AJ, Stewart FM, Quinn AJ, Walker ID, Greer IA. Low molecular weight heparin for the treatment of venous thromboembolism in pregnancy: a case series. Br. J. Obstet. Gynaecol.109(9), 1020–1024 (2002).
   Google Scholar
• Warkentin TE. Think of HIT when thrombosis follows heparin. Chest130(3), 631–632 (2006).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Sheppard JA, Moore JC, Moore KM, Sigouin CS, Kelton JG. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J. Lab. Clin. Med.146(6), 341–346 (2005).
   PubMed Web of Science ®Google Scholar
• Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb. Haemost.70(4), 554–561 (1993).
   PubMed Web of Science ®Google Scholar
• Douketis JD, Ginsberg JS, Burrows RF, Duku EK, Webber CE, Brill-Edwards P. The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study. Thromb. Haemost.75(2), 254–257 (1996).
   PubMed Web of Science ®Google Scholar
• Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb. Haemost.71(1), 7–11 (1994).
   PubMed Web of Science ®Google Scholar
• McKenna R, Cole ER, Vasan U. Is warfarin sodium contraindicated in the lactating mother? J. Pediatr.103(2), 325–327 (1983).
   PubMed Web of Science ®Google Scholar
• Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest126(3 Suppl.), 627S–644S (2004).
   PubMed Web of Science ®Google Scholar
• Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest119(1 Suppl.), 122S–131S (2001).
   PubMed Web of Science ®Google Scholar
• Krivak TC, Zorn KK. Venous thromboembolism in obstetrics and gynecology. Obstet. Gynecol.109(3), 761–777 (2007).
   PubMed Web of Science ®Google Scholar
• Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. Circulation93(12), 2212–2245 (1996).
   Google Scholar
• Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N. Engl. J. Med.336(21), 1506–1511 (1997).
   PubMed Web of Science ®Google Scholar
• Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am. J. Obstet. Gynecol.168(4), 1265–1270 (1993).
   PubMed Web of Science ®Google Scholar
• Demers C, Ginsberg JS. Deep venous thrombosis and pulmonary embolism in pregnancy. Clin. Chest Med.13(4), 645–656 (1992).
   PubMed Web of Science ®Google Scholar
• Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am. J. Obstet. Gynecol.174(5), 1584–1589 (1996).
   PubMed Web of Science ®Google Scholar
• Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br. Med. J.314(7076), 253–257 (1997).
   PubMed Web of Science ®Google Scholar
• Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis JS. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb. Haemost.83(5), 693–697 (2000).
   PubMed Web of Science ®Google Scholar
• Carp H, Dolitzky M, Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J. Thromb. Haemost.1(3), 433–438 (2003).
   PubMed Web of Science ®Google Scholar
• Gris JC, Mercier E, Quere I et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood103(10), 3695–3699 (2004).
   PubMed Web of Science ®Google Scholar
• Brenner B, Hoffman R, Carp H, Dulitsky M, Younis J. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study. J. Thromb. Haemost.3(2), 227–229 (2005).
   PubMed Web of Science ®Google Scholar
• Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost.4(2), 295–306 (2006).
   PubMed Web of Science ®Google Scholar
• Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb. Haemost.74(4), 1185–1190 (1995).
   PubMed Web of Science ®Google Scholar
• Wisloff F, Jacobsen EM, Liestol S. Laboratory diagnosis of the antiphospholipid syndrome. Thromb. Res.108(5–6), 263–271 (2002).
   PubMed Web of Science ®Google Scholar
• Tincani A, Allegri F, Sanmarco M et al. Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations – a cooperative project of the European Antiphospholipid Forum. Thromb. Haemost.86(2), 575–583 (2001).
   PubMed Web of Science ®Google Scholar
• Reber G, Tincani A, Sanmarco M, de Moerloose P, Boffa MC. Proposals for the measurement of anti-β2-glycoprotein I antibodies. Standardization group of the European Forum on Antiphospholipid Antibodies. J. Thromb. Haemost.2(10), 1860–1862 (2004).
   PubMed Web of Science ®Google Scholar